Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalised Immunotherapy Platform (PIP) - Implementation of a Predictive Model of Response to Immunotherapies in Melanoma

NCT06536257 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT06536257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalised Immunotherapy Platform (PIP) - Implementation of a Predictive Model of Response to Immunotherapies in Melanoma
Lead sponsor
Melanoma Institute Australia
Phase
Observational
Overall status
Recruiting
Start date
June 8, 2021
Completion date
June 1, 2037
Enrollment
1,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma, merkel cell carcinoma, solid tumor